Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Licenses Proteome Sciences' Isobaric Mass Tags

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has exclusively licensed rights to Proteome Sciences’ TMT isobaric mass tag technology, the Cobham, UK-based firm announced yesterday.
Proteome Sciences will manufacture the TMT reagents and Thermo Fisher will market and sell them through its Pierce product line. The TMT patents expire in 2021, and Thermo Fisher has the right to provide third-party commercial licenses for use of any type of isobaric tandem mass tags.
The mass tags are used with mass spectrometry for biomarker discovery, validation, and assay development.
Proteome Sciences retains rights to use the technology for its own research as well as custom labeling and assay development for customers using its TMTcalibrator and TMT Reference Materials. Financial terms of the deal were not disclosed, but Proteome Sciences said that it would receive a signature fee, contract manufacturing payments, and royalties and sales milestone payments.
Ian Jardine, vice president of global research and development for Thermo Fisher, said that the firm expects to make TMT products available during the second quarter of this year.
“By relying on Thermo Fisher’s comprehensive sales channels for volume catalog products, Proteome Sciences can focus on custom labeling services and products,” Proteome Sciences CEO Christopher Pearce said in a statement. “We see considerable demand for these services and anticipate that they will generate substantial and rapidly growing revenues.”

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.